Epidarex Capital – Portfolio Company Enterprise Therapeutics” Lead Program Acquired by Roche
October 7, 2020
Enterprise Therapeutics’ first-in-class TMEM16A potentiator program is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit